103 related articles for article (PubMed ID: 16512982)
1. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer.
Haura EB; Livingston S; Coppola D
Clin Lung Cancer; 2006 Jan; 7(4):273-5. PubMed ID: 16512982
[TBL] [Abstract][Full Text] [Related]
2. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
[TBL] [Abstract][Full Text] [Related]
4. Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma.
Labbozzetta M; Notarbartolo M; Poma P; Giannitrapani L; Cervello M; Montalto G; D'Alessandro N
Ann N Y Acad Sci; 2006 Nov; 1089():268-75. PubMed ID: 17261774
[TBL] [Abstract][Full Text] [Related]
5. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.
Luppi F; Longo AM; de Boer WI; Rabe KF; Hiemstra PS
Lung Cancer; 2007 Apr; 56(1):25-33. PubMed ID: 17175059
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells.
Zhu YM; Webster SJ; Flower D; Woll PJ
Br J Cancer; 2004 Nov; 91(11):1970-6. PubMed ID: 15545974
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
[TBL] [Abstract][Full Text] [Related]
9. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
[TBL] [Abstract][Full Text] [Related]
11. Autocrine IL-6 signaling: a key event in tumorigenesis?
Grivennikov S; Karin M
Cancer Cell; 2008 Jan; 13(1):7-9. PubMed ID: 18167335
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor signaling in non-small-cell lung cancer.
Semrad TJ; Mack PC
Clin Lung Cancer; 2012 Mar; 13(2):90-5. PubMed ID: 21959109
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome analysis of individual stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model.
Choi H; Sheng J; Gao D; Li F; Durrans A; Ryu S; Lee SB; Narula N; Rafii S; Elemento O; Altorki NK; Wong ST; Mittal V
Cell Rep; 2015 Feb; 10(7):1187-201. PubMed ID: 25704820
[TBL] [Abstract][Full Text] [Related]
14. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.
Rusch V; Baselga J; Cordon-Cardo C; Orazem J; Zaman M; Hoda S; McIntosh J; Kurie J; Dmitrovsky E
Cancer Res; 1993 May; 53(10 Suppl):2379-85. PubMed ID: 7683573
[TBL] [Abstract][Full Text] [Related]
16. Human non-small cell lung cancer cells express a type 2 cytokine pattern.
Huang M; Wang J; Lee P; Sharma S; Mao JT; Meissner H; Uyemura K; Modlin R; Wollman J; Dubinett SM
Cancer Res; 1995 Sep; 55(17):3847-53. PubMed ID: 7641203
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism.
Takizawa H; Ohtoshi T; Ohta K; Yamashita N; Hirohata S; Hirai K; Hiramatsu K; Ito K
Cancer Res; 1993 Sep; 53(18):4175-81. PubMed ID: 8364912
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node.
Saintigny P; Kambouchner M; Ly M; Gomes N; Sainte-Catherine O; Vassy R; Czernichow S; Letoumelin P; Breau JL; Bernaudin JF; Kraemer M
Lung Cancer; 2007 Nov; 58(2):205-13. PubMed ID: 17686546
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
Seto T; Higashiyama M; Funai H; Imamura F; Uematsu K; Seki N; Eguchi K; Yamanaka T; Ichinose Y
Lung Cancer; 2006 Jul; 53(1):91-6. PubMed ID: 16697074
[TBL] [Abstract][Full Text] [Related]
20. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
